Comparative effectiveness and cost-effectiveness of natalizumab and fingolimod in rapidly evolving severe relapsing-remitting multiple sclerosis in the United Kingdom.

Journal: Journal of medical economics

Publication Year: 2023

Authors & Co-authors:  Spelman T T Herring W L WL Acosta C C Hyde R R Jokubaitis V G VG Pucci E E Lugaresi A A Laureys G G Havrdova E K EK Horakova D D